Tuberculosis preventive therapy in the era of HIV infection: Overview and research priorities

被引:55
作者
Churchyard, Gavin J.
Scano, Fabio
Grant, Alison D.
Chaisson, Richard E.
机构
[1] Aurum Inst Hlth Res, ZA-2107 Gauteng, South Africa
[2] Univ KwaZulu Natal, CAPRISA, Natal, RN, Brazil
[3] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England
[4] WHO, Stop TB Dept, CH-1211 Geneva, Switzerland
[5] Johns Hopkins Univ, Ctr TB Res, Baltimore, MD 21218 USA
关键词
D O I
10.1086/518662
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The recognition of tuberculosis ( TB) as a major cause of morbidity and mortality among human immunodeficiency virus (HIV)-infected persons has led to renewed interest in TB preventive therapy and its incorporation into the essential package of health care for these individuals. Despite convincing data regarding its efficacy, TB preventive therapy has not been widely implemented. Further work is needed to determine how to overcome the barriers to the implementation of such therapy, including how best to exclude the presence of active TB before providing preventive therapy. Such issues as the optimal duration of preventive therapy for and the role of TB preventive therapy in the treatment of individuals receiving antiretroviral therapy remain to be defined. Ongoing research will help to determine how best to use this intervention in the care of HIV-infected persons and in the control of TB on a wider basis.
引用
收藏
页码:S52 / S62
页数:11
相关论文
共 82 条
[21]   Does tuberculosis increase HIV load? [J].
Day, JH ;
Grant, AD ;
Fielding, KL ;
Morris, L ;
Moloi, V ;
Charalambous, S ;
Puren, AJ ;
Chaisson, RE ;
De Cock, KM ;
Hayes, RJ ;
Churchyard, GJ .
JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (09) :1677-1684
[22]   Chemoprophylaxis for tuberculosis and survival of HIV infected patients in Brazil [J].
de Pinho, AMF ;
Santoro-Lopes, G ;
Harrison, LH ;
Schechter, M .
AIDS, 2001, 15 (16) :2129-2135
[23]   Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally [J].
Dye, C ;
Watt, CJ ;
Bleed, DM ;
Hosseini, SM ;
Raviglione, MC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (22) :2767-2775
[24]   Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial [J].
Fitzgerald, DW ;
Desvarieux, M ;
Severe, P ;
Joseph, P ;
Johnson, WD ;
Pape, JW .
LANCET, 2000, 356 (9240) :1470-1474
[25]  
Fitzgerald DW, 2001, J ACQ IMMUN DEF SYND, V28, P305
[26]   Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: The example of Zambia [J].
Foster, S ;
GodfreyFaussett, P ;
Porter, J .
AIDS, 1997, 11 (07) :919-925
[27]  
FRANKS AL, 1989, PUBLIC HEALTH REP, V104, P151
[28]   Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection [J].
Girardi, E ;
Antonucci, G ;
Vanacore, P ;
Libanore, M ;
Errante, I ;
Matteelli, A ;
Ippolito, G .
AIDS, 2000, 14 (13) :1985-1991
[29]  
Goletti D, 1996, J IMMUNOL, V157, P1271
[30]  
GOLUB JE, 2006, 16 INT AIDS C TOR